Merck KGaA Partners with Remepy to Pioneer "Hybrid Drugs" Combining Pharmaceuticals with Digital Therapeutics
核心洞察
Merck KGaA has entered into a collaboration with Israeli-US startup Remepy (搜索) to develop "Hybrid Drugs (搜索)" that combine traditional pharmaceuticals with personalized mobile app-based digital therapies, marking the first major pharmaceutical company foray into this emerging therapeutic area.
The partnership will initially focus on multiple US-based programs targeting a confidential rare cancer (搜索) indication, where drug-software solutions can provide significant value by addressing limited patient access to care and information.
Remepy (搜索) reports that in certain Hybrid Drug trials, the combination approach can double the effect size of standalone drugs through multidisciplinary care, potentially overcoming traditional drug ceiling effects.
Merck KGaA has entered into a collaboration agreement with Israeli-US startup Remepy (搜索) to explore the therapeutic potential of "Hybrid Drugs (搜索)" that combine traditional pharmaceuticals with personalized, mobile app-based digital therapies. This partnership represents the first major pharmaceutical company venture into this emerging area of digital therapeutics, aiming to boost patient outcomes beyond what drugs can achieve alone.
Targeting Rare Cancer with Integrated Approach
The collaboration will initially focus on multiple US-based programs targeting a confidential rare cancer (搜索) indication. According to Dr. Michal Tsur, co-founder and co-CEO of Remepy (搜索), drug-software solutions are particularly valuable in rare disease contexts where patients often have limited access to care and information that mobile applications can help provide.
The partnership may expand into additional therapeutic areas within Merck KGaA's broader portfolio in the future, though specific plans remain undisclosed. Under the agreement, Remepy (搜索) will be eligible for development support, milestone payments, and royalties on any sales if combination therapies reach commercialization, although financial details have not been disclosed.
Enhanced Efficacy Through Combination Therapy
Remepy (搜索)'s platform integrates traditional pharmacological treatments with software-guided therapies that may include motor, physical, and cognitive interventions delivered alongside medication. The approach is based on research suggesting that treatment outcomes improve when medication is combined with behavioral, physical, and cognitive interventions.
Dr. Tsur reports that in certain Hybrid Drug trials, the combination approach can double the effect size of standalone drugs through multidisciplinary care, potentially overcoming traditional drug ceiling effects. This dual-pronged method allows physicians to prescribe combinations where both the drug and digital therapeutic components are clinically validated with known effect sizes when used together.
Regulatory Pathways and Market Differentiation
For drug-digital therapy combinations to reach market, the digital therapeutic component must undergo Phase I-III clinical trials similar to traditional medicines. In the US, companies have two regulatory options available for bringing such combinations to market.
The first is the traditional combination product pathway, where drug-software combinations are approved as new, singular treatments. Alternatively, companies can leverage the Prescription Drug Use-Related Software (PDURS) framework to secure label expansion for existing drugs to include digital therapeutic effects.
While US regulators are becoming increasingly open to digital technologies in this context, the European Medicines Agency has yet to introduce a policy similar to PDURS. Dr. Tsur believes pressure will likely mount on European regulators to implement such policies when pharmaceutical companies launch products in the US market.
Strategic Considerations for Success
For integrated drug-digital therapeutics to succeed, Dr. Tsur notes that solutions should be developed for indications with unmet needs and strong disease heterogeneity, where combinations are most likely to demonstrate meaningful effect sizes. She emphasizes the importance of selecting indications where patients are already seeking non-pharmaceutical adjunct treatment options, as these patients are more likely to adhere to treatment and derive benefits.
From an efficacy standpoint, mechanistic data should be gathered on how digital therapeutics and drugs collectively impact clinical scales, biomarkers, and surrogate endpoints within diseases. This approach helps prove how and why combination therapies may eclipse the benefits of medicines' independent effects, offering stronger clinical validation.
The collaboration between Merck KGaA and Remepy (搜索) aims to commercialize drug-software combinations as singular products, a feat that no other industry player has yet achieved. As the pharmaceutical industry seeks new ways to improve patient outcomes, this integrated approach offers potential differentiation in increasingly crowded drug markets while avoiding reimbursement hurdles associated with standalone digital therapies.